Phase IIa Clinical Study of Efficacy and Safety of Injectable Recombinant Human Thymosin Beta 4 in Patients With Acute Myocardial Infarction
Latest Information Update: 10 Aug 2022
At a glance
- Drugs Recombinant human thymosin beta4 Beijing Northland Biotech (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- Sponsors Beijing Northland Biotech
Most Recent Events
- 10 Aug 2022 New trial record